The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Betahistine Mesilate Tablets (6mg) from National Medical Products Administration of China (the "NMPA"), being the first of such approval for the PRC entities, under type 4 chemical drug and regarded as passing the consistency evaluation. As stated in the Company's announcement dated 27 June 2024, the Group's Betahistine Mesilate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Betahistine Mesilate Tablet is mainly used in the treatment of dizziness and lightheadedness associated with Meniere's disease, Meniere's syndrome and vertigo.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.